Forward Pharma CFO to Participate in Three Investor Conferences in September
FBR's Second Annual Healthcare 1-on-1 Conference to be held at the Four Seasons in
Boston, Massachusettson Wednesday, September 9th.
Wells Fargo2015 Healthcare Conference to be held at the Hyatt Regencyin Boston, Massachusetts. Mr. Sendek will present on Thursday, September 10th at 1:20 PM EDT.
Morgan Stanley Global Healthcare Conferenceto be held at the Grand Hyattin New York, New York. Mr. Sendek will present on Wednesday, September 16th at 11:05 AM EDT.
Investors and other interested parties may access a live audio webcast of the conference presentations by visiting the investor page on the Company's website (www.forward-pharma.com). The audio replay will be available via our website for 90 days post the presentation.
Our principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K,
Forward Pharma A/S Media Contact:
Forward Looking Statements:
Certain statements in this press release may constitute "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as "believe," "expect," "anticipate," "hope," "would" and "potential." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's ability to obtain, maintain and defend issued patents with protective claims; the issuance and term of patents; the Company's ability to prevail in or obtain a favorable decision in any patent interference or infringement action; the Company's ability to recover damages in any such action; uncertainties relating to our development plans and activities, including the commencement of any clinical trial and the results, timing, cost and location thereof; risks and uncertainties related to the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties. These and other factors are identified and described in detail in certain of our filings with the